Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8006 vs investigator’s choice chemotherapy in platinum‑resistant ovarian cancer (phase III)
CTR20251345Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BAT8006 in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Bio-Thera Solutions, Ltd.. Started Jun 2025; status: active.
02
Drugs
BAT8006
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20251345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251345.